Investors

Osagie Imasogie (Chairman) and Oludare Odumosu (Global CEO) take investors and analysts through the top line comparative trial results of Zelira’s diabetic nerve pain drug vs Lyrica® including efficacy, safety and next steps for the organisation.

Chairman Osagie Imasogie and CEO Oludare Odumosu lead a presentation on the creation of an SPV and US $8.6M cornerstone funding from Cantheon Capital LLC for HOPE 1 Ph.2 and Ph.3 US FDA clinical trials.

H&P’s updated report on Zelira highlighted by the completed enrolment of participants in the diabetic nerve pain trial

Zelira Therapeutics Chairman Osagie Imasogie and Global CEO Oludare Odumosu present a company update at the 2022 Annual General Meeting.

Zelira Global CEO Oludare Odumosu provides Proactive with an update on the company’s progress with its proprietary revenue-generating products, global expansion and its pipeline of candidates undergoing clinical development.

Zelira to launch a suite of new cannabinoid-based products in FY22 – Proactive

Zelira Therapeutics and Curtin University partner on research of proprietary technology that demonstrates significant uptake of CBD into the brain

Zelira Therapeutics Investor Slide Deck

Zelira Therapeutics forms exclusive licensing deal to distribute its HOPE products in Washington DC

Some excerpt